| 2025 | A systematic study of changes in monoamine neurotransmitters in the rat brain following acute administration of alpha-methyltryptamine (AMT), 5-methoxy-alpha-methyltryptamine (5-MeO-AMT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT).Li K, Li N, Chen Y, Li X, Qiao Y, Wang D, Di B, Xu P · Neuroscience researchdoi:10.1016/j.neures.2025.04.006 | moderate | consumed | 3 sections |
| 2025 | Dual Modulation of 5-HT2A Receptors and SERT by α-Ethyltryptamine and Its Optical Isomers.Silverman JM, Fiorillo M, Younkin J, Jones CB, Maltman JL, Herszenhorn I, et al. · ACS chemical neurosciencedoi:10.1021/acschemneuro.5c00468 | moderate | consumed | 5 sections |
| 2025 | Effects of three tryptamines: alpha-methyltryptamine, 5-methoxy-alpha-methyltryptamine, and 5-methoxy-N,N-diisopropyltryptamine on acute toxicity, locomotor activity, and hallucinogenic behavior in mice.Li K, Li N, Chen Y, Li X, Qiao Y, Wang D, Di B, Xu P · Behavioural pharmacologydoi:10.1097/fbp.0000000000000841 | moderate | consumed | cited only |
| 2024 | Alpha-methyltryptamine (Indopan) - NCATS Inxight DrugsNCATS/NIHurl:20cb97e3473fcc7c | weak | consumed | cited only |
| 2024 | Alpha-methyltryptamine and 5-(2-methylaminopropyl)-benzofuran (5-MAPB) fatal co-intoxication: case report and review of literatureEpain M, Cartiser N, Bevalot F, Bottinelli C, Chatenay C, Fanton L · International Journal of Legal Medicinedoi:10.1007/s00414-024-03236-w | weak | consumed | 1 section |
| 2024 | Legal Status of Alpha-methyltryptamine - Multiple JurisdictionsVarious (Wikipedia, WebSearch)url:c29bc5afd23f85d7 | weak | consumed | cited only |
| 2023 | Alpha-methyltryptamine (alpha-MT) Metabolite Profiling in Human Hepatocyte Incubations and Postmortem Urine and BloodMalaca S, Bottinelli C, Fanton L, Cartiser N, Carlier J, Busardo FP · Metabolitesdoi:10.3390/metabo13010092 | moderate | consumed | 2 sections |
| 2023 | Release.org.uk - AMT Drug InformationRelease UKurl:3ad72d5c592d8337 | weak | consumed | cited only |
| 2022 | Serotonin toxicity of serotonergic psychedelicsMalcolm B, Thomas K · Psychopharmacologydoi:10.1007/s00213-021-05876-x | moderate | consumed | 2 sections |
| 2022 | Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Micede la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J · ACS Chemical Neurosciencedoi:10.1021/acschemneuro.2c00170 | moderate | consumed | 2 sections |
| 2021 | New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review.Schifano F, Chiappini S, Miuli A, Corkery JM, Scherbaum N, Napoletano F, Arillotta D, Zangani C, Catalani V, Vento A, Pettorruso M, Martinotti G, Massimo DG, Guirguis A · Experimental neurologydoi:10.1016/j.expneurol.2021.113638 | strong | consumed | 2 sections |
| 2020 | Designer drugs: mechanism of action and adverse effectsLuethi D, Liechti ME · Archives of Toxicologydoi:10.1007/s00204-020-02693-7 | strong | consumed | 2 sections |
| 2019 | 5-Methoxy-alpha-methyltryptamine (5-MeO-AMT), a tryptamine derivative, induces head-twitch responses in mice through the activation of serotonin receptor 2a in the prefrontal cortex.Abiero A, Botanas CJ, Sayson LV, Custodio RJ, de la Pena JB, Kim M, Lee HJ, Seo JW, Ryu IS, Chang CM, Yang JS, Lee YS, Jang CG, Kim HJ, Cheong JH · Behavioural brain researchdoi:10.1016/j.bbr.2018.07.020 | moderate | consumed | 3 sections |
| 2017 | In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks.Wagmann L, Brandt SD, Kavanagh PV, Maurer HH, Meyer MR · Toxicology lettersdoi:10.1016/j.toxlet.2017.03.007 | moderate | consumed | 4 sections |
| 2015 | Recreational use, analysis and toxicity of tryptamines.Tittarelli R, Mannocchi G, Pantano F, Romolo FS · Current neuropharmacologydoi:10.2174/1570159x13666141210222409 | moderate | consumed | cited only |
| 2015 | The hallucinogenic world of tryptamines: an updated review.Araújo AM, Carvalho F, Bastos Mde L, Guedes de Pinho P, Carvalho M · Archives of toxicologydoi:10.1007/s00204-015-1513-x | strong | consumed | 3 sections |
| 2014 | AMT Drug Information - DrugWiseDrugWise UKurl:3c1fc77ba0385127 | weak | consumed | cited only |
| 2014 | Patterns of presentation and clinical toxicity after reported use of alpha methyltryptamine in the United Kingdom. A report from the UK National Poisons Information Service.Kamour A, James D, Spears R, Cooper G, Lupton DJ, Eddleston M, Thompson JP, Vale AJ, Thanacoody HK, Hill SL, Thomas SH · Clinical toxicology (Philadelphia, Pa.)doi:10.3109/15563650.2014.885983 | moderate | consumed | 1 section |
| 2005 | Fatality due to acute alpha-methyltryptamine intoxication.Boland DM, Andollo W, Hime GW, Hearn WL · Journal of analytical toxicologypmid:16105268 | weak | consumed | 2 sections |
| 2004 | Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule.DEA Deputy Administrator · Federal Registerpmid:15455477 | moderate | consumed | 2 sections |
| 2003 | Schedules of controlled substances: temporary placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into Schedule I. Final rule.DEA Deputy Administrator · Federal Registerpmid:12678045 | moderate | consumed | 2 sections |
| 1986 | The effects of monoamine oxidase inhibitors on the ejaculatory response induced by 5-methoxy-N,N-dimethyltryptamine in the rat.Rényi L · British journal of pharmacologypmid:3091132 | moderate | consumed | 1 section |
| — | Searched ClinicalTrials.gov for "alpha-methyltryptamine AMT tryptamine" — no resultsabsence | no results | — |